Format

Send to

Choose Destination
Am J Hematol. 2008 Mar;83(3):233-6.

Pharmacogenetics of morphine: Potential implications in sickle cell disease.

Author information

1
Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC 20010, USA. ddarbari@cnmc.org

Abstract

Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine.

PMID:
17722074
DOI:
10.1002/ajh.21027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center